Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...
Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...
On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...
Shares of Pyxis Oncology dropped after the pharmaceutical company said data from its trials on a treatment for a form of head and neck cancer showed a high incidence of adverse effects. The stock fell ...
BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...
When patients begin receiving care at St. Luke's Same Day Surgery Center in April, they'll receive medications through a computerized pharmacy system that's been in use throughout St. Luke's Regional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback